Literature DB >> 11319587

Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria.

P Woodard1, W Wang, N Pitts, E Benaim, E Horwitz, J Cunningham, L Bowman.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal disease of hematopoiesis due to a mutation in the PIG-A gene. Affected patients may demonstrate hemolysis or venous thrombosis, and may develop MDS or aplastic anemia. Successful results may be obtained after conditioning and transplantation from syngeneic or genotypically matched sibling donors. Experience with transplantation from matched unrelated donors (MUD) is limited to eight patients, with only one survivor. We report three patients who underwent successful MUD BMT for PNH. All three patients had severe aplastic anemia (SAA) and PNH at the time of BMT. Unrelated donors were six-antigen HLA-matched (n = 2) or HLA-A mismatched (n = 1). Conditioning consisted of cytarabine, cyclophosphamide, TBI, and ATG. Grafts were T cell-depleted by anti-CD6/CD8 antibodies + complement. Further GVHD prophylaxis consisted of cyclosporine. Patients received 0.7-1.1 x 10(8) nucleated cells/kg and 1.1-2.1 x 10(6) CD34(+) cells/kg. Neutrophil engraftment occurred at 16-21 days. One patient developed grade 1 acute GVHD. Although all three patients experienced significant transplant-related complications, they ultimately resolved and all patients are alive and well 30-62 months after BMT. T cell-depleted MUD BMT is an effective treatment option for PNH-related MDS and SAA.

Entities:  

Mesh:

Year:  2001        PMID: 11319587     DOI: 10.1038/sj.bmt.1702827

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  6 in total

Review 1.  Diagnosis and management of paroxysmal nocturnal hemoglobinuria.

Authors:  Charles Parker; Mitsuhiro Omine; Stephen Richards; Jun-Ichi Nishimura; Monica Bessler; Russell Ware; Peter Hillmen; Lucio Luzzatto; Neal Young; Taroh Kinoshita; Wendell Rosse; Gerard Socié
Journal:  Blood       Date:  2005-07-28       Impact factor: 22.113

Review 2.  Paroxysmal Nocturnal Hemoglobinuria: From Bench to Bed.

Authors:  Amrallah A Mohammed; Hani El-Tanni; Tariq Al-Malki Atiah; Arwa Al-Malki Atiah; Marwan Al-Malki Atiah; Ayman A Rasmy
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-12       Impact factor: 0.900

3.  Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders.

Authors:  Lauri M Burroughs; Akiko Shimamura; Julie-An Talano; Jennifer A Domm; Kelsey K Baker; Colleen Delaney; Haydar Frangoul; David A Margolis; K Scott Baker; Eneida R Nemecek; Amy E Geddis; Brenda M Sandmaier; H Joachim Deeg; Rainer Storb; Ann E Woolfrey
Journal:  Biol Blood Marrow Transplant       Date:  2017-06-07       Impact factor: 5.742

4.  Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Authors:  Stella Santarone; Andrea Bacigalupo; Antonio M Risitano; Elena Tagliaferri; Erminia Di Bartolomeo; Anna Paola Iori; Alessandro Rambaldi; Emanuele Angelucci; Alessandra Spagnoli; Federico Papineschi; Stefania Tamiazzo; Marta Di Nicola; Paolo Di Bartolomeo
Journal:  Haematologica       Date:  2009-12-08       Impact factor: 9.941

5.  Acute myocardial infarction in a Chinese patient with paroxysmal nocturnal hemoglobinuria: A case report.

Authors:  Gang Li; Rui Hu; Yifang Gao
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

6.  Hematopoietic Stem Cell Transplantation for Patients with Paroxysmal Nocturnal Hemoglobinuria with or without Aplastic Anemia: A Multicenter Turkish Experience

Authors:  Fergün Yılmaz; Nur Soyer; Güldane Cengiz Seval; Sinem Civriz Bozdağ; Pervin Topcuoğlu; Ali Ünal; Leylagül Kaynar; Gökhan Özgür; Gülsan Sucak; Hakan Göker; Mustafa Velet; Hakan Özdoğu; Mehmet Yılmaz; Emin Kaya; Ozan Salim; Burak Deveci; İhsan Karadoğan; Güray Saydam; Fahri Şahin; Filiz Vural
Journal:  Turk J Haematol       Date:  2021-05-31       Impact factor: 1.831

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.